Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial

A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.